Cupid , the contraceptives manufacturer, has projected that Q3 FY26 will be its best-performing quarter so far, driven by sustained demand momentum and smooth operational execution. The company's optimistic outlook comes despite its stock experiencing a 20.00% decline on Friday following profit booking after a strong 13-day rally.

Strong Financial Outlook and Record Order Book

The company maintains confidence in its financial trajectory, with management indicating they remain on track to exceed earlier guidance for the fiscal year:

Cupid's record-high order book provides strong revenue visibility for the coming quarters, supported by operating efficiencies, stable demand, and execution progress. The company's capacity expansion work at the Maharashtra Palava facility continues as scheduled, aligning with its broader operational roadmap.

FMCG Portfolio Expansion and Product Performance

The company's FMCG portfolio continues to demonstrate robust growth across India, supported by expanding retail presence in personal care and wellness categories. Recently launched products have shown promising market reception:

• Petroleum Jelly
• Face Wash
• Talcum Powder

These new product launches have received encouraging consumer response, contributing to the overall demand momentum across Cupid's diversified product portfolio.

International Expansion Plans

Following the company board's in-principle approval, the proposed FMCG manufacturing facility in Saudi Arabia is intended to support regional demand and improve supply timelines across the GCC and nearby export markets.

Stock Performance and Market Activity

Despite the positive business outlook, Cupid shares experienced significant volatility, plunging 20.00% amid profit booking. This decline ended an impressive 13-session unbeaten rally that had delivered 34.00% gains. The stock reached a 52-week high of ₹526.95 on Thursday, with trading volumes exceeding 2.00 crore shares.

The multibagger stock has delivered exceptional returns of 452.00% over the past one-year period, reflecting strong investor confidence in the company's growth trajectory and market positioning in the contraceptives and FMCG segments.

Cupid Ltd has reported positive returns on its strategic investment, with the company's stake in the GII Healthcare Fund appreciating significantly since the initial investment. The FMCG company announced that its investment has grown to approximately 1.2 times the original amount invested in October 2025.

Investment Performance Overview

The company's investment in the GII Healthcare Fund has demonstrated solid performance, delivering returns that exceed the initial capital deployed. This appreciation reflects the fund's successful investment strategy within the healthcare sector.

Strategic Investment Impact

The positive performance of this investment adds value to Cupid's overall portfolio diversification strategy. The company's decision to invest in a healthcare-focused fund appears to have yielded favorable results, contributing to the company's financial position beyond its core FMCG operations.

This development showcases Cupid's approach to capital allocation and its ability to identify investment opportunities that generate returns for shareholders. The 20% appreciation over the initial investment amount represents a meaningful contribution to the company's investment portfolio performance.